Clinical Trial Update: SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SGLT2 inhibitors for neuroprotection in patients with acute ischemic stroke; current status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Acute Ischemic Stroke | Phase 3 | Status: NOT_YET_RECRUITING